Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates <i>In Vitro</i> and in a Mouse Model of Pulmonary Infection
Danielle A. Nicklas, Emily C. Maggioncalda, Elizabeth Story-Roller, Benjamin Eichelman, Chavis Tabor, Alisa W. Serio, Tiffany R. Keepers, Surya Chitra, Gyanu Lamichhane
Abstract
The incidence of nontuberculous mycobacterial diseases in the United States is rising and has surpassed that of tuberculosis. Most notable among the nontuberculous mycobacteria is Mycobacteroides abscessus , an emerging environmental opportunistic pathogen capable of causing chronic infections. M. abscessus disease is difficult to treat, and the current treatment recommendations include repurposed antibiotics, several of which are associated with undesirable side effects.
Topics & Concepts
Mycobacterium abscessusMedicineNontuberculous mycobacteriaAntibioticsLinezolidPotencyPharmacologyTetracyclineAntibacterial agentLungMicrobiologySurgeryImmunologyMinimum inhibitory concentrationBronchoalveolar lavageAntagonismLung diseaseEffective dose (radiation)GastroenterologyInternal medicineRespiratory diseasePharmacokineticsPulmonary diseaseProtein synthesis inhibitorMycobacterium research and diagnosisTuberculosis Research and EpidemiologyDiphtheria, Corynebacterium, and Tetanus